Association between hydrocortisone use and outcomes in sepsis patients with hospital-acquired bloodstream infections: An ancillary analysis of the EUROBACT-2 cohort.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42743132.
- Also identified by DOI 10.1371/journal.pone.0356721.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Corticosteroids are suggested for selected patients with septic shock, but their association with outcomes has not been specifically investigated in patients with hospital-acquired bloodstream infections (HA-BSI). We explored the association between hydrocortisone use and day-28 mortality in this population. Data from the prospective EUROBACT-2 study were used to assess the association between hydrocortisone use and day-28 mortality in ICU patients with HA-BSI and sepsis. Patients receiving hydrocortisone were compared with patients not receiving hydrocortisone. A 1:1 propensity score matching procedure was performed using nearest-neighbour matching without replacement and a caliper of 0.2 standard deviation of the logit propensity score, followed by multivariable logistic regression with cluster-robust standard errors by matched pair. Among 2,401 analyzed patients, 608 (25%) received hydrocortisone during the HA-BSI episode. The final propensity score included age, sex, Charlson comorbidity score, ICU admission diagnosis, SOFA score without cardiovascular component, septic shock, country of inclusion, lactate at HA-BSI diagnosis, and ICU-acquired versus non-ICU-acquired HA-BSI. Matching yielded 521 pairs (1,042 patients). In the multivariable model, hydrocortisone use was associated with increased day-28 mortality in the overall matched cohort (OR 1.448; 95% CI 1.096-1.914; p = 0.009). This association was observed in patients with sepsis without shock (OR 1.697; 95% CI 1.051-2.740; p = 0.031) and in the female subgroup (OR 1.718; 95% CI 1.055-2.796; p = 0.030), but not in patients with septic shock or in those receiving norepinephrine-equivalent dose ≥0.25 µg/kg/min. Hydrocortisone use was not associated with improved day-28 survival in ICU patients with HA-BSI. In the matched analysis, hydrocortisone use was associated with higher day-28 mortality in the overall cohort, whereas no significant association was observed in patients with septic shock or high-dose norepinephrine. These findings are observational and hypothesis-generating and should not be interpreted causally.
Medical subject headings
- Hydrocortisone
- Sepsis
- Cross Infection